PURPOSE: Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is reported to be re-expressed in malignant tumors and can regulate the expression of multiple genes related to tumor invasion. CD44 standard isoform (CD44s) has been reported to play an important role in facilitating tumor invasion. In this text, we investigate the regulatory function of IMP3 on CD44s and the role of IMP3 and CD44s in predicting the outcomes of patients with hepatocellular carcinoma. METHODS: IMP3 and CD44s were measured in hepatocellular carcinoma (HCC) tissues by immunohistochemical assay, and survival analysis was conducted among 128 patients. Moreover, we studied the effect of IMP3 on the expression of CD44s and the biological functions of tumor cells in HCC cell lines. RESULTS: Our results showed that the expression of IMP3 was significantly correlated with CD44s expression (r = 0.505, P < 0.001), and both of them correlated with high AFP level, advanced tumor stage and grade, portal vein tumor thrombus, and early tumor recurrence or metastasis. The results of survival analysis exhibited that the 1-, 3-, 5-year disease-free and overall survival rates significantly reduced in IMP3- and CD44s-positive patients, and IMP3 combined with CD44s was an independent prognostic risk factor for HCC. In vitro assay, our results showed that IMP3 promoted HepG2 and MHCC97H cells invading and migrating via regulating CD44s expression. CONCLUSIONS: Our findings suggest that IMP3 facilitates HCC aggressiveness through regulating CD44s expression, and IMP3 combined with CD44s can be as a new predictor for unfavorable prognosis in HCC patients.
PURPOSE:Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is reported to be re-expressed in malignant tumors and can regulate the expression of multiple genes related to tumor invasion. CD44 standard isoform (CD44s) has been reported to play an important role in facilitating tumor invasion. In this text, we investigate the regulatory function of IMP3 on CD44s and the role of IMP3 and CD44s in predicting the outcomes of patients with hepatocellular carcinoma. METHODS:IMP3 and CD44s were measured in hepatocellular carcinoma (HCC) tissues by immunohistochemical assay, and survival analysis was conducted among 128 patients. Moreover, we studied the effect of IMP3 on the expression of CD44s and the biological functions of tumor cells in HCC cell lines. RESULTS: Our results showed that the expression of IMP3 was significantly correlated with CD44s expression (r = 0.505, P < 0.001), and both of them correlated with high AFP level, advanced tumor stage and grade, portal vein tumor thrombus, and early tumor recurrence or metastasis. The results of survival analysis exhibited that the 1-, 3-, 5-year disease-free and overall survival rates significantly reduced in IMP3- and CD44s-positive patients, and IMP3 combined with CD44s was an independent prognostic risk factor for HCC. In vitro assay, our results showed that IMP3 promoted HepG2 and MHCC97H cells invading and migrating via regulating CD44s expression. CONCLUSIONS: Our findings suggest that IMP3 facilitates HCC aggressiveness through regulating CD44s expression, and IMP3 combined with CD44s can be as a new predictor for unfavorable prognosis in HCC patients.
Authors: John Nemunaitis; Thomas Meyers; Neil Senzer; Casey Cunningham; Howard West; Eric Vallieres; Stephen Anthony; Svetislava Vukelja; Barry Berman; Heather Tully; Beena Pappen; Stephen Sarmiento; Rosemarie Arzaga; Steven Duniho; Susan Engardt; Madeleine Meagher; Martin A Cheever Journal: Mol Ther Date: 2006-04-11 Impact factor: 11.454
Authors: Lioudmila Sitnikova; Gary Mendese; Qin Liu; Bruce A Woda; Di Lu; Karen Dresser; Sambit Mohanty; Kenneth L Rock; Zhong Jiang Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun-Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F Wiggins; Andreas G Bader; Randy Fagin; David Brown; Dean G Tang Journal: Nat Med Date: 2011-01-16 Impact factor: 53.440
Authors: Phuc V Pham; Nhan L C Phan; Nhung T Nguyen; Nhung H Truong; Thuy T Duong; Dong V Le; Kiet D Truong; Ngoc K Phan Journal: J Transl Med Date: 2011-12-07 Impact factor: 5.531
Authors: Emanuel Adelino M Damasceno; Fabiana Pirani Carneiro; Albino Verçosa de Magalhães; Marcos de Vasconcelos Carneiro; Gustavo Henrique Soares Takano; Leonora Maciel de Sousa Vianna; Heinrich Bender Kohnert Seidler; Tercia Maria Mendes Lousa de Castro; Maria Imaculada Muniz-Junqueira; Rivadávio Fernandes Batista Amorim; Vânia Maria Moraes Ferreira; Andrea Barreto Motoyama Journal: J Cancer Res Clin Oncol Date: 2014-10-17 Impact factor: 4.553
Authors: Jennifer M Wickens; Hashem O Alsaab; Prashant Kesharwani; Ketki Bhise; Mohd Cairul Iqbal Mohd Amin; Rakesh Kumar Tekade; Umesh Gupta; Arun K Iyer Journal: Drug Discov Today Date: 2016-12-23 Impact factor: 7.851